Systematic pan‐cancer analysis insights into ICAM1 as an immunological and prognostic biomarker
- 9 July 2024
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23802
Abstract
Intercellular adhesion molecule 1 (ICAM1) is a cell surface adhesion glycoprotein in the immunoglobulin supergene family. It is associated with several epithelial tumorigenesis processes, as well as with inflammation. However, the function of ICAM1 in the prognosis of tumor immunity is still unclear. This study aimed to examine the immune function of ICAM1 in 33 tumor types and to investigate the prognostic value of tumors. Using datasets from the Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), Cancer Cell Lines Encyclopedia (CCLE), Human Protein Atlas (HPA), and cBioPortal, we investigated the role of ICAM1 in tumors. We explored the potential correlation between ICAM1 expression and tumor prognosis, gene mutations, microsatellite instability, and tumor immune cell levels in various cancers. We observed that ICAM1 is highly expressed in multiple malignant tumors. Furthermore, ICAM1 is negatively or positively associated with different malignant tumor prognoses. The expression levels of ICAM1 were correlated with the tumor mutation burden (TMB) in 11 tumors and with MSI in eight tumors. ICAM1 is a gene associated with immune infiltrating cells, such as M1 macrophages and CD8+ T cells in gastric and colon cancer. Meanwhile, the expression of ICAM1 is associated with several immune‐related functions and immune‐regulation‐related signaling pathways, such as the chemokine signaling pathway. Our study shows that ICAM1 can be used as a prognostic biomarker in many cancer types because of its function in tumorigenesis and malignant tumor immunity.Keywords
This publication has 51 references indexed in Scilit:
- RelB promotes the migration and invasion of prostate cancer DU145 cells via exosomal ICAM1 in vitroCellular Signalling, 2022
- Inactivation of ICAM1 inhibits metastasis and improves the prognosis of Ewing's sarcomaJournal of Cancer Research and Clinical Oncology, 2020
- MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinomaCancer Treatment Reviews, 2020
- Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapyCancer Letters, 2020
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018European Journal of Cancer, 2018
- A novel combined score of biomarkers in sputum may be an indicator for lung cancer: A pilot studyClinica Chimica Acta, 2018
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerCancer Cell, 2018
- The Immune Landscape of CancerImmunity, 2018
- Tumor microenvironment and therapeutic responseCancer Letters, 2017
- Supergene families meet in the immune systemImmunology Today, 1988